Morning Overview on MSN
A new FDA-approved pill just won fast-tracked approval for an aggressive blood cancer — a drug that flips off the survival switch keeping lymphoma cells alive
For the roughly 4,000 to 5,000 Americans diagnosed with mantle cell lymphoma each year, running out of treatment options can happen fast. The cancer is one of the more aggressive forms of non-Hodgkin ...
MedPage Today on MSN
Next-Gen BCL2 Inhibitor Approved for Aggressive Lymphoma
Sonrotoclax (Beqalzi) indicated for relapsed or refractory mantle cell lymphoma ...
A little over a year after being diagnosed with non-Hodgkin lymphoma, Dave Coulier announced exclusively on the TODAY show that he is undergoing treatment for an unrelated tongue cancer. The actor, ...
MSK hematologist-oncologist Dr. Lia Palomba led a clinical trial that resulted in FDA approval of lisocabtagene maraleucel (Breyanzi®), a CAR T cell therapy, for marginal zone lymphoma. Marginal zone ...
Miami basketball player Marcus Allen will miss the rest of the season due to a non-Hodgkin lymphoma diagnosis. The sophomore guard began chemotherapy treatment this week, according to his family.
Radiation therapy (also called radiotherapy) uses high-energy beams or atoms to damage the DNA inside cancer cells. After enough damage, the cells cannot multiply, and they die. Based on your subtype ...
Morning Overview on MSN
A new drug just won fast-tracked approval for an aggressive blood cancer — a pill that flips off the survival switch keeping lymphoma cells alive
When mantle cell lymphoma stops responding to treatment, the options narrow fast. This rare but aggressive form of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results